By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen will provide molecular diagnostics screening to women in Rwanda as part of a national cervical cancer prevention effort announced today.

As part of the initiative announced by Merck, Qiagen, and the government of Rwanda, Qiagen will provide screening for women between the ages of 35 and 45, and Merck will vaccinate girls between 12 and 15 years of age during the first three years of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.